Don, can we add what Harvey said, "the release of information on new indications for all three of their compounds. Today, we just had the release for the pan-FGFR inhibitor for Pona, which is one. '113 will have one beyond NSCLC, and Rida will have another..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.